Efficacy of Anti-SDF-1 Neutralizing Antibody in a Corneal Inflammation Model (IMAGE)
Caption
<p>(A) From left to right, WT (wild-type) mice as the control group, the Dscr-1+ApoE-deficient group, and the Dscr-1+ApoE-deficient group treated with anti-SDF-1 neutralizing antibody. Each group was subjected to corneal inflammation (* indicates the site of injury), and the subsequent angiogenesis (CD31, red) and lymphangiogenesis (LYVE1, green) from the peri-corneal area (dashed line) are shown. </p> <p>(B & C) Angiogenesis progression (B) and lymphangiogenesis progression (C) were quantified. Significant difference tests were performed compared to WT (*) and Dscr-1+ApoE deficiency (#) mouse models respectively (P<0.05). </p>
Credit
Professor Takashi Minami
Usage Restrictions
<p>Fig. 6(A, B, & C) of <a href="https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.315003">Muramatsu, M. et al. (2020). Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 40(10), 2425-2439. doi:10.1161/atvbaha.120.315003</a>. </p> <p>Use of the material in any format is prohibited without written permission from the publisher, Wolters Kluwer Health, Inc. Please contact permissions@lww.com for further information. </p>
License
Licensed content